NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
Clinical Trials
11 trialsNCT05928962 2023-07-10
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
Fujian Cancer Hospital
Phase 1 Unknown
NCT03994393 2023-04-21
ILLUMINATE
University of Sydney
Phase 2 Unknown
NCT03975114 2023-03-24
MILES-5
National Cancer Institute, Naples
Phase 2 Unknown
NCT03737968 2023-03-21
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Yonsei University
Phase 2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT03450967 2021-08-10
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Samsung Medical Center
Phase 2 Unknown
NCT03699449 2021-04-01
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Yonsei University
Phase 2 Unknown
NCT03377400 2020-12-17
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Samsung Medical Center
Phase 2 Unknown
NCT01655888 2012-08-02
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown
NCT01649024 2012-07-25
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown